Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Zesheng Wan"'
Autor:
Emad Darvishi, Katherine Slemmons, Zesheng Wan, Sheetal Mitra, Xiaogang Hou, Jean Hugues Parmentier, Yong-Hwee Eddie Loh, Lee J. Helman
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 7, Pp 274-282 (2020)
Fibroblast growth factor receptor 4 (FGFR4) aberrant expression and activity have been linked to the pathogenesis of a variety of cancers including rhabdomyosarcomas (RMS). We found that treatment of alveolar rhabdomyosarcoma (aRMS) cells with Guadec
Externí odkaz:
https://doaj.org/article/e8a5345bdc5d48c5b2b326717e165c49
Autor:
Yongsheng Ruan, Hye Na Kim, Heather A. Ogana, Zesheng Wan, Samantha Hurwitz, Cydney Nichols, Nour Abdel-Azim, Ariana Coba, Seyoung Seo, Yong-Hwee Eddie Loh, Eun Ji Gang, Hisham Abdel-Azim, Chih-Lin Hsieh, Michael R. Lieber, Chintan Parekh, Dhananjaya Pal, Deepa Bhojwani, Donald L. Durden, Yong-Mi Kim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The PI3K/Akt pathway—and in particular PI3Kδ—is known for its role in drug resistant B-cell acute lymphoblastic leukemia (B-ALL) and it is often upregulated in refractory or relapsed B-ALL. Myc proteins are transcription factors responsible for
Externí odkaz:
https://doaj.org/article/9d2a16f695cc4722b8574521dd391e56
Autor:
Margarita Gutova, Leanne Goldstein, Marianne Metz, Anahit Hovsepyan, Lyudmila G. Tsurkan, Revathiswari Tirughana, Lusine Tsaturyan, Alexander J. Annala, Timothy W. Synold, Zesheng Wan, Robert Seeger, Clarke Anderson, Rex A. Moats, Philip M. Potter, Karen S. Aboody
Publikováno v:
Molecular Therapy: Oncolytics, Vol 4, Iss C, Pp 67-76 (2017)
Despite improved survival for children with newly diagnosed neuroblastoma (NB), recurrent disease is a significant problem, with treatment options limited by anti-tumor efficacy, patient drug tolerance, and cumulative toxicity. We previously demonstr
Externí odkaz:
https://doaj.org/article/5c7db55070fa4313a9cda696861dc9fa
Autor:
Eugene S. Kim, Robert C. Seeger, Larry Wang, Michael A. Sheard, Jemily Malvar, Zesheng Wan, Jianping Sun, Hong-Wei Wu, Grace E. Asuelime, Jeremy R. Jackson, Wesley E. Barry
Supplemental Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a0abd074e8ee922c2222979d83e83e
https://doi.org/10.1158/1078-0432.22474272
https://doi.org/10.1158/1078-0432.22474272
Autor:
Eugene S. Kim, Robert C. Seeger, Larry Wang, Michael A. Sheard, Jemily Malvar, Zesheng Wan, Jianping Sun, Hong-Wei Wu, Grace E. Asuelime, Jeremy R. Jackson, Wesley E. Barry
GD2 expression levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a12127e3c2f2582cc59db5e6ecea526a
https://doi.org/10.1158/1078-0432.22474275
https://doi.org/10.1158/1078-0432.22474275
Autor:
Robert C. Seeger, Shahab Asgharzadeh, Eugene S. Kim, Richard Sposto, Larry Wang, Yibing Xu, Jemily Malvar, Jeremy R. Jackson, Jianping Sun, Michael A. Sheard, Zesheng Wan, Hung C. Tran
Purpose: Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC). Galunisertib, an inhibitor of TGFβR1, was examined for its ability to enhance the efficacy of din
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79dd1c1306a9854a3bc935fb1a442f40
https://doi.org/10.1158/1078-0432.c.6525567
https://doi.org/10.1158/1078-0432.c.6525567
Autor:
Robert C. Seeger, Shahab Asgharzadeh, Eugene S. Kim, Richard Sposto, Larry Wang, Yibing Xu, Jemily Malvar, Jeremy R. Jackson, Jianping Sun, Michael A. Sheard, Zesheng Wan, Hung C. Tran
Supplementary Figure S2 shows the results of intracellular staining of aNK cells for perforin and granzyme A, as requested by reviewer #3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53fb6e314a960e6812233d18a757775e
https://doi.org/10.1158/1078-0432.22463907
https://doi.org/10.1158/1078-0432.22463907
Autor:
Robert C. Seeger, Shahab Asgharzadeh, Eugene S. Kim, Richard Sposto, Larry Wang, Yibing Xu, Jemily Malvar, Jeremy R. Jackson, Jianping Sun, Michael A. Sheard, Zesheng Wan, Hung C. Tran
Supplementary Table S1 is a list of antibodies used in the study. It has been updated to include antibodies used in experiments requested by reviewer #3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae046af45e3263be94355393c0a871b4
https://doi.org/10.1158/1078-0432.22463901.v1
https://doi.org/10.1158/1078-0432.22463901.v1
Autor:
Eugene S. Kim, Robert C. Seeger, Larry Wang, Michael A. Sheard, Jemily Malvar, Zesheng Wan, Jianping Sun, Hong-Wei Wu, Grace E. Asuelime, Jeremy R. Jackson, Wesley E. Barry
Purpose:Immunotherapy of neuroblastoma that remains after myeloablative chemotherapy with anti-GD2 antibody dinutuximab has increased the two-year event-free and overall survival of high-risk neuroblastoma patients; however, 40% of patients develop r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6747c2cdb7d30876f7915e65f49fd1
https://doi.org/10.1158/1078-0432.c.6528741.v1
https://doi.org/10.1158/1078-0432.c.6528741.v1
Autor:
Hsiao-Chuan Liu, Eun Ji Gang, Hye Na Kim, Yongsheng Ruan, Heather Ogana, Zesheng Wan, Halvard Bönig, K. Kirk Shung, Yong-Mi Kim
Publikováno v:
Cells, Vol 9, Iss 6, p 1470 (2020)
Drug resistance is an obstacle in the therapy of acute lymphoblastic leukemia (ALL). Whether the physical properties such as the motility of the cells contribute to the survival of ALL cells after drug treatment has recently been of increasing intere
Externí odkaz:
https://doaj.org/article/30672be8be56480c9375232af11d1257